Patient-Reported Outcomes After Ferric Carboxymaltose Treatment for Iron Deficiency Anemia: A Prospective...

Area of Science:

• Internal Medicine
• Hematology
• Clinical Nutrition

Background:

• Iron deficiency anemia (IDA) is a prevalent condition leading to fatigue and reduced quality of life.
• Intravenous iron supplementation is a key treatment for IDA.

Purpose of the Study:

• To assess the impact of intravenous ferric carboxymaltose (FCM) on fatigue, physical function, and general health in routine clinical care for IDA patients.

Main Methods:

• Prospective, single-arm, observational study involving 152 adult patients with IDA.
• Utilized PROMIS instruments to measure fatigue, general health, and physical function pre-treatment and at 3 and 6 months post-FCM.
• Assessed changes in serum hemoglobin levels.

Main Results:

• Significant improvements in fatigue (FACIT-Fatigue scores) were observed at 3 months post-FCM (p < 0.0001), sustained at 6 months.
• Clinically meaningful improvements in physical and global health were reported by a substantial percentage of patients.
• Mean serum hemoglobin levels increased significantly at 3 and 6 months post-treatment.

Conclusions:

• Intravenous FCM effectively ameliorates fatigue, physical function, and general health impairments in IDA patients within routine clinical settings.
• The positive effects of FCM treatment on patient-reported outcomes are sustained for at least six months.